The Reimbursement IQ subject matter experts—in collaboration with our longstanding strategic partners at Central IQ—are offering briefings on “Performance, Outcomes, and Impact Analytics” to innovators, entrepreneurs, and executives within Life Science companies.
These Zoom-based or remote briefings can help transform Medical Affairs, HEOR/Value, Market Access, and Commercialization (Marketing and Sales) functions by revealing the extreme visibility that data science is bringing to the U.S. healthcare market—especially to individuals, employers, and other healthcare purchasers.
Health plan buyers want more value for their money—and Life Science leaders need to understand the level of transparency that data science gives those bearing the burden of healthcare cost escalation.
In an April 5, 2018 report, the Pharmaceutical Research and Manufacturers Association (PhRMA) highlighted 39 value-based contracts between pharmaceutical companies and savings-minded healthcare stakeholders. The bulk of these purchasing arrangements centered on discounted, bundled, capitated, pay-for-performance, and outcomes-driven pricing for payers.
Next-generation contracts will move toward 360-degree performance, outcomes, and impact accountability across stakeholders. Data science vendors are offering healthcare purchasers greater visibility into the human, business, and social results of clinical interventions. The Life Science sector can no longer expect business as usual.
Reimbursement IQ’s briefings describe the competencies that mission-driven Life Science companies need to win next-generation value-based contracts; to meet new performance, outcomes, and impact accountabilities; and to deliver real, lasting healthcare results.
The briefings feature three health industry pioneers and how each has improved performance, outcomes, and impacts at the level of community care, healthcare, and self-care. Life Science leaders get first-hand exposure to state-of-the-art data visualizations, dashboards, and scorecards that provide real-time reporting on the well-being, productive capacity, and socioeconomic status of individuals, organizations, and communities.
With 360-degree accountability on the horizon, Life Science executives learn how their Medical Affairs, Market Access, and Marketing teams should use impact analytics to
- improve economic, clinical, and humanistic outcomes (ECHOs);
- achieve the Triple/Quadruple/Quintuple Aim of reduced per capita costs, improved population health, enhanced patient and provider experiences, and boosted health equity;
- reduce the incidence, prevalence, and cost of diseases and other adverse conditions;
- increase the wellbeing, productive capacity, and socioeconomic status of individuals, organizations, and communities; and
- contribute to a better functioning society.
Briefed on U.S. healthcare’s digital transformation and growing transparencies, Life Science leaders attending “Performance, Outcomes, and Impact Analytics” gain strategic advantages in value-based contracting (VBC) and outcomes-based compensation (OBC).
To learn more about performance, outcomes, and impact analytics—and how to develop markets, companies, and products with these ends in mind—call us today at +1 949-336-1691 or schedule a Zoom at https://bit.ly/3MQ2MoG